- All
- 2024/05/10
- 2024/05/11
- All
- Main Venue (DongFang 1 Ballroom 3F )
- Sub-Venue1（FuYue 2 Ballroom 3F）
- Sub-Venue2（FuYue 3 Ballroom 3F）
- Sub-Venue3（MingZhu Ballroom 3F）
- Sub-Venue4（No.8 Conference Room 3F）
- Sub-Venue5（No.9 Conference Room 3F）
2024/05/11
Sub-Venue1（FuYue 2 Ballroom 3F）
| 1 | 08:00-08:05 | Speech |
Opening ceremony |
|
||||
| 2 | 08:05-08:10 | Speech |
Opening ceremony |
|
||||
| 3 | 08:10-08:15 | Speech |
Opening ceremony |
|
||||
| 1 | 08:15-09:15 | Other |
Enterprise Assistance Symposium |
|||||
| 2 | 08:15-08:45 | Symposium |
Baricitinib, what every dermatologist should know |
|
||||
| 3 | 08:45-09:15 | Symposium |
How PsoHo study supports clinical decision making in Plaque Psoriasis |
|
||||
| 4 | 09:15-09:35 | Other |
Enterprise Assistance Symposium |
|||||
| 5 | 09:15-09:35 | Symposium |
IL-36 pathway takes key role in GPP |
|
||||
| 1 | 09:35-09:55 | Symposium |
Research Advances in Immunotherapy of Melanoma |
|
||||
| 2 | 09:55-10:15 | Symposium |
Delayed inflammatory reactions after tissue filling |
|
||||
| 1 | 10:25-10:40 | Symposium |
The role of aminoacyl-tRNA synthetases in the pathogenesis of psoriasis |
|
||||
| 2 | 10:40-10:55 | Symposium |
Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the PRRERCT (Prospective Rosacea Refractory Erythema Randomized Clinical Trial) |
|
||||
| 3 | 10:55-11:10 | Symposium |
Exploration of SJS/TEN from Clinical Aspects to Molecular Mechanisms |
|
||||
| 1 | 11:10-11:25 | Symposium |
Cutaneous T Cell Lymphoma: New subtyping, new mechanism, and new advances |
|
||||
| 2 | 11:25-11:40 | Symposium |
The pathogenesis of drug induced adverse reactions: new progress |
|
||||
| 1 | 11:40-11:55 | Symposium |
New insights in the immunopathogenesis of psoriasis |
|
||||
| 2 | 11:55-12:10 | Symposium |
Role and application of skin microbiome in atopic dermatitis |
|
||||
| 3 | 12:10-12:30 | Other |
Enterprise Assistance Symposium |
|||||
| 4 | 12:10-12:30 | Symposium |
New developments in GPP long-term management |
|
||||
| 1 | 12:30-12:45 | Lunch Symposium |
Exploring the Unique Value Proposition of Home Beauty Devices in Light of Evolving Regulatory Standards |
|
||||
| 2 | 12:45-13:00 | Lunch Symposium |
Clinical Applications of Yellow and Red LED Light Therapy in Managing Sensitive Skin Conditions |
|
||||
| 1 | 13:00-13:20 | Lunch Symposium |
Pioneering Integrated Skincare in China |
|
||||
| 2 | 13:20-13:30 | Lunch Symposium |
Healing and microbiome: From Knowledge to Dermatological Innovations ——Latest findings on the role of Microbiome in wound healing |
|
||||
| 3 | 13:30-13:50 | Lunch Symposium |
Healing and microbiome: From Knowledge to Dermatological Innovations ——How microbiome research can benefit Dermocosmetics |
|
||||
| 4 | 13:50-14:00 | Lunch Symposium |
Healing and microbiome: From Knowledge to Dermatological Innovations —— Clinical study results of a new repair product: from superficial wounds to post procedure benefits |
|
||||
| 1 | 14:00-14:15 | Symposium |
Non-bullous autoimmune bullous diseases |
|
||||
| 2 | 14:15-14:30 | Symposium |
Cutaneous deposition disorders: Tips and tricks |
|
||||
| 3 | 14:30-14:45 | Symposium |
Non-Langerhans cell histiocytosis |
|
||||
| 4 | 14:45-15:00 | Symposium |
Clinicopathological spectrum and treatment of cutaneous T-cell lymphomas |
|
||||
| 5 | 15:00-15:15 | Symposium |
Acral melanoma |
|
||||
| 6 | 15:15-15:30 |
Q & A |
||||||
| 1 | 16:00-16:15 | Symposium |
PIEZO2 transduces pruritogen-induced alloknesis. |
|
||||
| 2 | 16:15-16:30 | Symposium |
Peripheral mechanism of diabetic pruritus |
|
||||
| 3 | 16:30-16:45 | Symposium |
Latest Insights into Prurigo Nodularis Pathogenesis and Management |
|
||||
| 4 | 16:45-17:00 | Symposium |
Neuroimmune Circuits in Atopic Dermatitis and Relevance for treatment Options |
|
||||
| 5 | 17:00-17:15 | Symposium |
Hereditary angioedema: what the dermatologist needs to know? |
|
||||
| 6 | 17:15-17:30 | Discussion |
Q & A |
|||||